Reversal agent controls bleeding risk with DOACS used for stroke prevention

For patients receiving stroke prevention therapy with an oral factor Xa inhibitor, the reversal agent andexanet has been shown to markedly reduce anti-factor Xa activity where there is life-threatening or uncontrolled bleeding. The final results of the ANNEXA-4 study,  presented at the International Stroke Conference in Hawaii, showed andexanet rapidly and markedly reduces anti-factor Xa activity in patients ...

Already a member?

Login to keep reading.

© 2021 the limbic